Pharmacogovernance
| Autor: | Jillian Clare Kohler, Kathy Moscou |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Government
Public economics Corruption business.industry 030503 health policy & services Corporate governance media_common.quotation_subject Supply chain 03 medical and health sciences Patient safety 0302 clinical medicine Health care Pharmacovigilance Quality (business) 030212 general & internal medicine 0305 other medical science business media_common |
| Popis: | How national, state, and municipal governments establish priorities, make policy, and allocate resources are shaped by governance. Pharmacogovernance influences national and subnational policy choices (or lack thereof) for governing structures, policy instruments, institutional authority (e.g., ability to act, implement, and enforce norms, policies, and processes), and resource allocation to promote societal interests for patient safety and protections from adverse drug events. Developing countries are disproportionately affected by weak pharmacogovernance especially when it is accompanied by insufficient standards of national governance. Weak pharmacogovernance lessens government commitment to combat corruption; creates opportunities for spurious, substandard, falsely labeled, falsified, and counterfeit drugs to enter the supply chain; and enables regional inequities in pharmacovigilance. Poor governance is costly and wastes limited healthcare resources that might otherwise be used to provide quality and affordable care by increasing the cost of medicines, some of which may be unsafe or ineffective. Pharmacogovernance can improve postmarket drug safety by establishing (1) an internal policy framework for drug safety, (2) the active cultivation of organizational capabilities, (3) sustainable funding, and (4) external partnerships for drug safety. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|